Methods to identify breast cancer patients with an elevated risk profile based on CD163+ TAM-centered tumor markers have the potential to improve clinical management of patients by identifying patients with unfavorable prognosis and opening the way for alternative tumor immune-boosting strategies. Here, CD163 is linked to breast carcinoma.